| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/50-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | REV7; FANCV; MAD2B; POLZ2 |
| Entrez GeneID | 10459 |
| WB Predicted band size | Calculated MW: 24 kDa; Observed MW: 24 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human Mad2L2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于MAD2L2抗体的3篇代表性文献摘要：
---
1. **文献名称**：*MAD2B promotes DNA damage checkpoint via modulating the E2F1/p73 axis*
**作者**：Liu X, et al.
**摘要**：研究揭示了MAD2L2(MAD2B)通过调控E2F1/p73信号通路参与DNA损伤应答。利用特异性MAD2L2抗体进行免疫沉淀和Western blot实验，证实其与E2F1的相互作用，并发现MAD2B缺失导致细胞对DNA损伤的敏感性增加。
---
2. **文献名称**：*REV7/MAD2B interacts with CCDC8 and regulates PLK1 recruitment to maintain genome stability*
**作者**：Hara K, et al.
**摘要**：该研究通过免疫共沉淀(使用MAD2L2抗体)和质谱分析，鉴定出MAD2L2与CCDC8蛋白的结合，并发现这一复合物调控PLK1激酶的定位，从而在有丝分裂中维持基因组稳定性，为癌症治疗提供潜在靶点。
---
3. **文献名称**：*Development and validation of a monoclonal antibody specific for human MAD2L2 protein*
**作者**：Zhang Y, et al.
**摘要**：研究团队开发了一种高特异性的抗人MAD2L2单克隆抗体，通过ELISA、免疫组化和流式细胞术验证其灵敏度及特异性，证明该抗体能有效检测多种癌细胞系中MAD2L2的表达水平，为后续功能研究提供工具。
---
(注：以上文献信息为示例，实际引用需核对真实数据库。建议通过PubMed或Google Scholar以关键词“MAD2L2 antibody”或“REV7 antibody”获取最新研究。)
The MAD2L2 (Mitotic Arrest Deficient 2-Like 2) antibody is a tool used to detect and study the MAD2L2 protein, also known as REV7. MAD2L2 is a multifunctional protein involved in DNA repair, cell cycle regulation, and chromosome segregation. It plays a critical role in the Fanconi anemia (FA) pathway and translesion synthesis (TLS), a DNA damage tolerance mechanism. Structurally distinct from its homolog MAD2L1. MAD2L2 interacts with key partners like SHLD3 in the Shieldin complex and participates in DNA repair processes, including the regulation of FANCD2 activation. Its dysfunction is linked to genomic instability, tumorigenesis, and chemoresistance, particularly in cancers with defective homologous recombination repair (e.g., BRCA-mutated tumors).
MAD2L2 antibodies are widely used in research to investigate protein expression, localization, and interactions via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Studies employing these antibodies have revealed MAD2L2's overexpression in various cancers, correlating with poor prognosis and therapeutic resistance (e.g., platinum-based chemotherapy). Additionally, MAD2L2 is explored as a potential biomarker or therapeutic target due to its role in maintaining replication fork stability and modulating DNA repair pathways. These antibodies thus serve as essential reagents for dissecting mechanisms of genome maintenance and developing strategies to overcome treatment resistance in oncology.
×
